

## OriGene Technologies Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES Phone: +1-858-888-7900 Fax: +1-858-888-7904 <u>US-info@acris-antibodies.com</u>

## BP7122 OriGene EU

Acris Antibodies GmbH Schillerstr. 5 32052 Herford GERMANY Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info@acris-antibodies.com

## Polyclonal Antibody to MAPKAP Kinase 2 (MAPKAPK-2) pThr334 - Aff - Purified

Alternate names:	МАРКАРК2
Catalog No.:	BP7122
Quantity:	0.1 ml
Background:	Mitogen activated protein kinase-activated protein kinase-2 (MAPKAPK-2), expressed as alpha (~49 kDa) and beta (~60 kDa) isoforms, is phosphorylated by p38 MAPK and mediates multiple p38 MAPK-dependent cellular responses, including inflammation. MAPKAPK-2 is implicated in several disorders including brain ischemic injury and heart failure, and has shown to be important in regulating stress resistance and the production of tumor necrosis factor alpha (TNF-q). In unstimulated cells, MAPKAPK-2 is located in the nucleus where it contributes to CREB phosphorylation. Upon stimulation it translocates to the cytoplasm and phosphorylates and activates tuberin and HSP27. MAPKAPK-2 is phosphorylated in the kinase domain at threonine 222 (in the activation loop) and serine 272, and in the C-terminus at threonines 334 and 338. Threonine 334 is a major regulatory site, as once phosphorylated it induces conformational changes which result in the activation of the kinase.
Host:	Rabbit
Immunogen:	Chemically synthesized phosphopeptide derived from a region of human MAPKAPK-2 that contains threonine 334. Remarks: The sequence is conserved in mouse, hamster and rabbit.
Format:	<ul> <li>State: Liquid lg fraction</li> <li>Purification: Sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated MAPKAPK-2. The final product is generated by affinity chromatography using a MAPKAPK-2-derived peptide that is phosphorylated at threonine 334.</li> <li>Buffer System: Dulbecco's phosphate buffered saline (without Mg2+ and Ca2+), pH 7.3 (+/- 0.1), 50% glycerol, with 1.0 mg/mL BSA (lgG, protease free) as a carrier containing 0.05 % sodium azide as preservative.</li> </ul>
Applications:	Western blot (1:1000). Positive control: HeLa cells treated with TNF-α or anisomycin; NIH-3T3 cells treated with anisomycin. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Specificity:	This antibody detects MAPKAPK-2. <b>Species:</b> Human, mouse, hamster, rabbit. Other species not tested.

**For research and in vitro use only. Not for diagnostic or therapeutic work.** Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com



OG/20121030

1/5

	BP7122: Polyclonal Antibody to MAPKAP Kinase 2 (MAPKAPK-2) pThr334 - Aff - Purified
Storage:	Store at 2 - 8 °C up to one week or (in aliquots) at -20 °C for longer. Centrifuge vial before opening. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
General Readings:	Li, Y., et al. (2003) The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J. Biol. Chem. 278(16):13663-13671. Song, C., et al. (2002) beta-Amyloid peptide induces formation of actin stress fibers through p38 mitogen-activated protein kinase. J. Neurochem. 83(4):828-836. Wang, X., et al. (2002) Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J. Biol. Chem. 277 (46):43968-43972. Nakano, A., et al. (2000) Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. Circ. Res. 86(2):144-151. Verma, A., et al. (2000) Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J. Immunol. 168(12):5984-5988. Chevalier, D. and B.G. Allen (2000) Two distinct forms of MAPKAP kinase-2 in adult cardiac ventricular myocytes. Biochemistry. 39(20):6145-6156. Larsen, J.K., et al. (1997) Phosphorylation of the 27-kDa heat shock protein via p38 MAP kinase and MAPKAP kinase in smooth muscle. Am. J. Physiol. 273(5 Pt 1):L930-L940. Engel, K., et al. (1995) MAPKAP kinase 2 is activated by heat shock and TNF-alpha: in vivo phosphorylation of small heat shock protein results from stimulation of the MAP kinase cascade. J. Cell. Biochem. 57(2):321-330.
Protocols:	Western Blotting Procedure
	<ol> <li>Lyse approximately 10e7 cells in 0.5 mL of ice cold Cell Lysis Buffer (formulation provided below). This buffer, a modified RIPA buffer, is suitable for recovery of most proteins, including membrane receptors, cytoskeletal-associated proteins, and soluble proteins. Other cell lysis buffer formulations, such as Laemmli sample buffer and Triton-X 100 buffer, are also compatible with this procedure. Additional optimization of the cell stimulation protocol and cell lysis procedure may be required for each specific application.</li> <li>Remove the cellular debris by centrifuging the lysates at 14,000 x g for 10 minutes. Alternatively, lysates may be ultracentrifugedat 100,000 x g for 30 minutes for greater clarification.</li> <li>Carefully decant the clarified cell lysates into clean tubes and determine the protein concentration using a suitable method, such as the Bradford assay. Polypropylene tubes are recommended for storing cell lysates.</li> <li>React an aliquot of the lysate with an equal volume of 2x Laemmli Sample Buffer (125 mM Tris, pH 6.8, 10% glycerol, 10% SDS, 0.006% bromophenol blue, and 130 mM dithiothreitol [DTT]) and boil the mixture for 90 seconds at 100°C.</li> <li>Load 10-30 µg of the cell lysate into the wells of an appropriate single percentage or gradient minigel and resolve the proteins by SDS-PAGE.</li> <li>In preparation for the Western transfer, cut a piece of PVDF membrane slightly larger than the gel. Soak the membrane in methanol for 1 minutes.</li> <li>Assemble the gel and membrane into the sandwich apparatus.</li> <li>Transfer the proteins at 140 mA for 60-90 minutes at room temperature.</li> <li>Following the transfer, rinse the membrane with Tris buffered saline for 2 minutes.</li> <li>Block the membrane with blocking buffer (formulation provided below) for one hour at room temperature or overnight at 4°C.</li> </ol>

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com

2 / 5

OG/20121030

TUV NO.



12. Incubate the blocked blot with primary antibody at a 1:1000 dilution in Tris buffered saline supplemented with 3% BSA and 0.1% Tween 20 for one hour at room temperature or overnight at 4°C.

13. Wash the blot with several changes of Tris buffered saline supplemented with 0.1% Tween 20.

14. Detect the antibody band using an appropriate secondary antibody, such as goat F(ab)2 anti-rabbit IgG alkaline phosphatase conjugate or goat F(ab)2 anti-rabbit IgG horseradish peroxidase conjugate in conjunction with your chemiluminescence reagents and instrumentation.

Cell Lysis Buffer Formulation: 10 mM Tris, pH 7.4 100 mM NaCl 1 mM EDTA 1 mM EGTA 1 mM NaF 20 mM Na4P2O7 2 mM Na3VO4 0.1% SDS 0.5% sodium deoxycholate 1% Triton-X 100 10% glycerol 1 mM PMSF (made from a 0.3 M stock in DMSO) or 1 mM AEBSF (water soluble version of PMSF)  $60 \,\mu g/mL$  aprotinin  $10 \,\mu g/mL$  leupeptin 1µg/mL pepstatin (alternatively, protease inhibitor cocktail such as Sigma Cat. # P2714 may be used)

Transfer Buffer Formulation: 2.4 gm Tris base 14.2 gm glycine 200 mL methanol Q.S. to 1 liter, then add 1 mL 10% SDS. Cool to 4°C prior to use.

Tris Buffered Saline Formulation: 20 mM Tris-HCl, pH 7.4 0.9% NaCl

Blocking Buffer Formulation: 100 mL Tris buffered saline 5 gm BSA 0.1 mL Tween 20

Peptide Competition Experiment

The specificity of a Phosphorylation Site Specific Antibody (PSSA) in each experimental system can be confirmed through peptide competition. In this technique, aliquots of antibody are pre-incubated with peptide containing the sequence of the phosphopeptide immunogen used to raise the PSSA and the corresponding non-phosphopeptide. Following preincubation with the peptide, each antibody preparation is then used as a probe in

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com



OG/20121030



antibody-based detection methods, such as Western blotting, immunocytochemistry, flow cytometry, or ELISA. With a PSSA specific for the phosphorylated target protein, preincubation with an excess of peptide containing the sequence of the phosphopeptide immunogen will block all antigen binding sites, while pre-incubation with the corresponding non-phosphopeptide will not affect the antibody.

In performing the Peptide Competition Experiment, it is important to note that the optimal dilutions of both antibody and peptide should be determined empirically for each specific application. The optimal dilution of antibody in these procedures is below saturating, as determined by previous experiments in your system.

The optimal dilution of peptide used in these procedures will depend on the overall affinity or avidity of the antibody, as well as the quantity of the target antigen. A 50-150 fold molar excess of peptide to antibody is found to be effective for most peptide competition experiments.

In the example presented below, the PSSA is used as a dilution of 1:1000 and the peptides are used at a concentration of 333 nM. The total volume of the phosphopeptide and nonphosphopeptide pre-incubated antibody preparations is 2 mL, sufficient for probing Western blot strips, as well as for use in other antibody-based detection methods. Under these conditions, the molar excess of peptide to antibody is > / = 50.

## Procedure:

1. Prepare three identical test samples, such as identical PVDF or nitrocellulose strips to which the protein of interest has been transferred. The test samples should be blocked using a blocking buffer, such as Tris buffered saline supplemented with 0.1% Tween 20, and either 5% BSA or 5% non-fat dried milk.

2. Prepare 6.5 mL of working antibody stock solution (1:1000 in this example) by adding 6.5  $\mu$ L of antibody stock solution to 6.5 mL of buffer containing blocking protein, such as TBS supplemented with 0.1% Tween 20, and either 3% BSA or 3% non-fat dried milk.

3. Apportion the unused PSSA into working aliquots and store at -20°C for future use (the stock PSSA contains 50% glycerol and will not freeze at this temperature).

4. Allow the lyophilized control peptides to reach room temperature, ideally under desiccation. 5. Reconstitute each of the control peptides to a concentration of 66.7  $\mu$ M with nanopure water. (i.e. for a peptide with a molecular mass of 1500, reconstitution with 1 mL water yields a solution with a concentration of 66.7  $\mu$ M).

6. Apportion the unused reconstituted peptide solutions into working aliquots and store at -20°C for future use.

7. Label 3 test tubes as follows:

- tube 1: water only no peptide control
- tube 2: phosphopeptide
- tube 3: non-phosphopeptide

8. Into each tube, pipette the following components

- tube 1: 2 mL diluted PSSA solution plus 10  $\mu L$  nanopure water

- tube 2: 2 mL diluted PSSA solution plus 10 µL phosphopeptide

- tube 3: 2 mL diluted PSSA solution plus 10 µL non-phosphopeptide

9. Incubate the three tubes for 30 minutes at room temperature with gentle rocking. During this incubation, the peptides have the chance to bind to the combining site of the antibody.

10. At the end of the incubation step, transfer the contents of each of the three tubes to clean reaction vessels containing one of the three identical test samples. For Western blotting strips:

Incubate the strips with the pre-incubated antibody preparations for 1 hour at room temperature or overnight at 4°C.

Wash each strip four times, five minutes each, to remove unbound antibody. Transfer each strip to a new solution containing a labeled secondary antibody [e.g., goat F(ab)2 anti-

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com



OG/20121030




rabbit IgG alkaline phosphatase conjugate or goat F(ab)2 anti-rabbit IgG horseradish peroxidase conjugate.

Remove unbound secondary antibody by thorough washing, and develop the signal using your chemiluminescent reagents and instrumentation.

The signal obtained with antibody incubated with the "Water Only, No Peptide Control" (Tube 1), represents the maximum signal in the assay. This signal should be eliminated by preincubation with the "Phosphopeptide" (Tube 2), while pre-incubation with the "Non-Phosphopeptide" (Tube 3) should not impact the signal. If the "Phosphopeptide" only partially eliminates the signal, repeat the procedure using twice the volume of water or peptide solutions listed in Step 8. If partial competition is seen following pre-incubation with the "Non-Phosphopeptide", repeat the procedure using half the volumes of water or peptide solutions listed in Step 8.

**Pictures:** 

**Peptide Competition and Phosphatase** Treatment Lysates prepared from HeLa cells left untreated (1), treated with anisomycin (2), or TNF- $\alpha$  (3-7) were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were either left untreated (1-6) or treated with lambda ( $\lambda$ ) phosphatase (7), blocked with a 5% BSA-TBST buffer for one hour at room temperature, and incubated with MAPKAPK-2 [pT334] antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1-3, 7), the nonphosphopeptide corresponding to the immunogen (4), a generic phosphothreonine-containing peptide (5) or, the phosphopeptide immunogen (6). After washing, membranes were incubated with goat F(ab')2 anti-rabbit IgG HRP conjugate and bands were detected using the Pierce SuperSignalTM method. The data show that only the peptide corresponding to MAPKAPK-2 [pT334] blocks the antibody signal. The data also show that phosphatase stripping eliminates the signal, verifying that the antibody is phospho-specific.



For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request. Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com



OG/20121030